Pfizer Inc. (NYSE:PFE) Shares Sold by Steel Grove Capital Advisors LLC

Steel Grove Capital Advisors LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 75.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,980 shares of the biopharmaceutical company’s stock after selling 45,907 shares during the period. Steel Grove Capital Advisors LLC’s holdings in Pfizer were worth $431,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Worth Asset Management LLC acquired a new stake in Pfizer in the first quarter valued at $29,000. Briaud Financial Planning Inc bought a new stake in Pfizer during the third quarter valued at $30,000. Sanctuary Wealth Management L.L.C. bought a new stake in Pfizer during the fourth quarter valued at $50,000. Mizuho Securities Co. Ltd. bought a new stake in Pfizer during the third quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.7 %

PFE traded up $0.19 on Wednesday, reaching $27.78. 34,140,219 shares of the company traded hands, compared to its average volume of 43,897,863. The stock’s 50 day moving average price is $27.47 and its 200-day moving average price is $29.47. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $42.22. The company has a market cap of $157.31 billion, a price-to-earnings ratio of 77.17, a PEG ratio of 1.23 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.14 earnings per share. On average, sell-side analysts expect that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PFE. Barclays lowered their target price on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research note on Thursday, December 14th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Truist Financial cut their price objective on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Friday, March 1st. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.